Know Cancer

forgot password

Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients

Phase 2
18 Years
70 Years
Open (Enrolling)
Breast Cancer

Thank you

Trial Information

Phase II Trial of Adjuvant TC (Docetaxel/Cyclophosphamide) Plus Trastuzumab in HER2-Positive Early Stage Breast Cancer Patients

Inclusion Criteria:

A woman will be eligible for inclusion in this study if she meets all of the following

- Has HER2+ (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive
tumor cells], or a FISH result of .6 HER2 gene copies per nucleus or a FISH ratio
[HER2 gene signals to chromosome 17 signals] of >2.2; patients with equivocal FISH
ratio results 1.8-2.2 are also eligible if 3+ IHC) (Appendix IX); Stage I, IIA, IIB,
or IIIA T1-3N1-3M0 disease. At the discretion of the Treating Physician, patients
with 4+ nodes with other factors such as patient choice, older age, preexisting
cardiac disease with normal MUGA or ECHO may be enrolled into a separate subgroup.

- Has operable, histologically confirmed, invasive carcinoma of the breast.

- Has known ER and PR status

- Has adequate tumor specimen available for FISH analysis of TOP2A status (See Appendix

- Has had no prior chemotherapy unless it was given >5 years ago for breast cancer or
other cancer

- Has an ECOG Performance Status (PS) 0-1

- Age >18 to <70 years old.

- Has laboratory values of: See protocol for specific details

- Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline
phosphatase (ALP) within the ranges shown below. In determining eligibility the more
abnormal of the 2 values (AST or ALT) should be used. See protocol for specific

- Has complete surgical resection of the primary breast tumor: either lumpectomy or
mastectomy with sentinel lymph node or axillary dissection.

- It has been <84 days since the date of definitive surgery, and there is adequate
wound healing as determined by the Treating Physician

- Has no evidence of metastatic disease by physical examination and x-ray; appropriate
scans as needed by each individual patient (eg, bone scan; abdominal, chest CT; PET
or PET/CT; ultrasound; or MRI should indicate no evidence of metastatic disease.

- Has normal cardiac function as evidenced by a LVEF >50%, but must be within normal
limits (WNL) by institutional standard, as determined by multiple gated acquisition
(MUGA) scan. An echocardiogram (ECHO). The same modality must be used throughout the
study to evaluate LVEF. Ejection fraction (EF) as determined by ECHO must be WNL by
institutional standard.

- Has a negative serum pregnancy test within 7 calendar days prior to registration
(female patients of childbearing potential [not surgically sterilized and between
menarche and 1 year postmenopause]).

- If fertile, patient has agreed to use an acceptable method of birth control (barrier
contraceptive) to avoid pregnancy for the duration of the study and for a period of 3
months thereafter

- Has signed a Patient Informed Consent Form

- Has signed a Patient Authorization Form

Exclusion Criteria:

A woman will be excluded from this study if she meets any of the following criteria:

- Has any evidence of disease following complete surgical resection of the primary
tumor and metastatic workup

- Has Stage IIIB breast cancer (T4 disease; ie, patients with fixed tumors, peau
d'orange skin changes, skin ulcerations, or inflammatory changes).

- Has Stage IV breast cancer (M1 disease on TNM staging system)

- Had prior chemotherapy for breast cancer or other cancer within the last 5 years (no
neoadjuvant chemotherapy in this study is permitted)

- Has a history of severe hypersensitivity reaction to drugs formulated with
polysorbate 80

- Has had a myocardial infarction (MI) within 6 months of trial enrollment, or has New
York Heart Association (NYHA) Class II or greater heart failure (see Appendix III),
uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically
significant pericardial disease, or electrocardiographic evidence of acute ischemic

- Has abnormal baseline MUGA (or ECHO) (<50%, or less than institutional LLN)

- Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy.
Adjuvant hormonal therapy, if needed, may be given during radiation therapy and
during treatment with trastuzumab after completion of chemotherapy.

- Is receiving concurrent investigational therapy or has received such therapy within
the past 30 calendar days

- Has peripheral neuropathy >Grade 1

- Has a serious uncontrolled intercurrent medical or psychiatric illness, including
serious viral (including clinically defined AIDS), bacterial or fungal infection; or
history of uncontrolled seizures, or diabetes, or CNS disorders deemed by the
Treating Physician to be clinically significant, precluding informed consent

- Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is
known to be HIV positive

- Has a history of other malignancy within the last 5 years (except cured basal cell
carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the
diagnosis or assessment of any of the study drugs

- Is an obese patient to whom the Treating Physician would not be comfortable
administering full doses of study drugs as calculated by the BSA. Obese patients will
be treated based on actual body weight. Obese patients treated with full doses based
on actual BSA are eligible

- Is a pregnant or breastfeeding woman

- Is deemed unable to comply with requirements of study

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the DFS at 2 years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC patients treated with TC+H.

Outcome Time Frame:

To determine the DFS at 2 years

Safety Issue:


Principal Investigator

Stephen E Jones, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

US Oncology Research


United States: Institutional Review Board

Study ID:




Start Date:

June 2007

Completion Date:

February 2011

Related Keywords:

  • Breast Cancer
  • Breast Neoplasms



Texas Oncology, P.A. Dallas, Texas  75246
Virginia Oncology Associates Newport News, Virginia  23606
Comprehensive Cancer Centers of Nevada Las Vegas, Nevada  89109
Ocala Oncology Center Ocala, Florida  34474
Cancer Centers of the Carolinas Greenville, South Carolina  29605
Missouri Cancer Associates Columbia, Missouri  65201
New Mexico Cancer Care Associates Santa Fe, New Mexico  87505-7670
Tyler Cancer Center Tyler, Texas  75702
Hope Center Terre Haute, Indiana  47809
Willamette Valley Cancer Center Eugene, Oregon  97401-8122
San Antonio Tumor and Blood Clinic San Antonio, Texas  78217
New York Oncology Hematology, P.C. Albany, New York  12208
Cancer Centers of Florida, P.A. Orlando, Florida  
Northwest Cancer Specialists-Vancouver Vancouver, Washington  98684
Medical Oncology Associates Kingston, Pennsylvania  18704
Florida Cancer Institute New Port Richey, Florida  34652
Central Indiana Cancer Centers Indianapolis, Indiana  46227
Minnesota Oncology Hematology, P.A. Minneapolis, Minnesota  55407
Texas Cancer Center at Medical City Dallas, Texas  75230
Allison Cancer Center Midland, Texas  79701
Texoma Cancer Center Wichita Falls, Texas  76310
Highline Medical Oncology Burien, Washington  98166
Hematology Oncology Associates Phoenix, Arizona  85012
Arch Medical Services, INC. St. Louis, Missouri  63142
Greater Dayton Cancer Center Kettering, Ohio  45409
Birmingham Hematology and Oncology Birmingham, Alabama  35235
Texas Cancer Center Abilene, Texas  79606
Texas Oncology Cancer Center Austin, Texas  78731
Mamie McFaddin Ward Cancer Center Beaumont, Texas  77702
Lake Vista Cancer Center Lewisville, Texas  75067
Longview Cancer Center Longview, Texas  75601
Texas Cancer Center of Mesquite Mesquite, Texas  75150
Onc and Hem Associates of SW VA, Inc. Salem, Virginia  24153
Maryland Oncology Hematology, P.A. Columbia, Maryland  21044
Paris Regional Cancer Center Paris, Texas  75460
Hematology Oncology Associates of IL Chicago, Illinois  60611
Cancer Care & Hematology Specialists of Chicagoland Niles, Illinois  60714
Rocky Mountain Cancer Center-Rose Denver, Colorado  80220
Texas Oncology PA Dallas, Texas  75231
Hematology-Oncology Associates of NNJ, P.A. Morristown, New Jersey  07960
Interlakes Oncology Hematology, PC Rochester, New York  14623
El Paso Cancer Treatment Ctr El Paso, Texas  79915
South Texas Cancer Center-McAllen McAllen, Texas  78503
Texas Cancer Center-Sherman Sherman, Texas  75090
Texas Oncology Cancer Center-Sugar Land Sugar Land, Texas  77479
Puget Sound Cancer Center-Seattle Seattle, Washington  98133
Cancer Care Northwest-South Spokane, Washington  99202
Yakima Valley Mem Hosp/North Star Lodge Yakima, Washington  98902
Fairfax Northern VA Hem-Onc PC Fairfax, Virginia  22031
Puget Sound Cancer Center-Edmonds Edmonds, Washington  98026
Connecticut Oncology & Hematology, LLP Torrington, Connecticut  06790
Kansas City Cancer Centers-Southwest Overland Park, Kansas  66210
Ruth Oratz MD New York, New York  10016
Texas Oncology, P.A.-Amarillo Amarillo, Texas  79106
HOAST-Medical Dr. San Antonio, Texas  78229
Cancer Centers of North Carolina Raleigh, North Carolina  27607
Northern AZ Hematology & Oncology Associates Sedona, Arizona  86336
Arizona Oncology Associates DBA HOPE Tucson, Arizona  85704
Alliance Hematology Oncology P.A. Westminster, Maryland  21157
Texas Cancer Center-Abilene (South) Abilene, Texas  79606
Texas Oncology, P.A.-Bedford Bedford, Texas  76022
Methodist Charlton Cancer Ctr. Dallas, Texas  75237
Texas Oncology-Odessa Odessa, Texas  79761
Texas Oncology Cancer Care and Research Waco, Texas  76712